Pro Medicus : PME Signs Research Collaboration Agreement with Mayo Clinic

3 June 2021; Company Announcement - Mayo Clinic Research Collaboration Agreement - Acrobat pdf 125k

Highlights

• PME signs multi-year research collaboration agreement with Mayo Clinic
• Mayo Clinic to leverage the capabilities of the Visage AI Accelerator platform
• Collaboration to facilitate artificial intelligence (AI) research and development with a view to product commercialisation
• Builds on existing Mayo Clinic Visage 7 Viewer agreement

Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned U.S. subsidiary, Visage Imaging, Inc., has signed a multi-year research collaboration agreement with Mayo Clinic.

The agreement will serve as the framework for collaboration between the two parties to facilitate development and commercialisation in the field of AI leveraging the Visage AI Accelerator platform.

'Our AI Accelerator program was designed to closely align Visage's engineering and product development capability with clinical research partners such as Mayo Clinic who have a depth of clinical knowledge and extensive research expertise,' said Malte Westerhoff, PhD, Visage Imaging Global CTO. 'It provides a unique set of tools for data de-identification, collection, curation, analysis and 'path-to-production' in research projects bringing the efficiency and speed of Visage technology to research, resulting in a unified link between the two domains.'

Dr Westerhoff continued, 'We see AI playing a significant role in healthcare particularly in our field of imaging IT. We have optimized our Visage 7 platform for AI enabling both our own, as well as third-party algorithms to be seamlessly integrated into the clinician's desktop. We see this research collaboration agreement with Mayo Clinic as another significant piece of our AI strategy, one that has the potential to develop innovative AI solutions that meet well defined clinical goals and ultimately lead to better patient outcomes.'